Biocon inaugurates first US manufacturing facility in New Jersey

VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications

CRISPR-based detection enables highly specific molecular recognition

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach

FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

Sirio secures TGA GMP certification to support strategic growth in Australia

The Ma’anshan site approval covers pastilles, oral liquids, and powders

Alembic gets FDA final approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe

SPL Infusion commences commercial production of new IV fluid Infusion plant

The facility has been designed with a dual focus on efficiency and sustainability

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development

Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)

He has been associated with the Zydus Group since 2009